Editorial. Stimulant medications have been used to treat symptoms of attention deficit hyperactivity disorder (ADHD) for over 80 years, longer than the use of antibiotics to treat infection (1). Based on data from over 6 million individuals in an insurance database, the 2008 annual prevalence for filled stimulant prescriptions was found to be 4.6% for children ages 6–12 years, 3.7% for adolescents (13–18 years), and 1.6% for young adults (19–24 years) (2). These figures are in line with data from other studies (3) and are below the estimated 7% 1-year prevalence of childhood ADHD (4). The short-term efficacy of stimulants in ADHD is well established (5), yet despite eight decades of clinical use, there continues to be angst over it. Reviews call attention to the fact that there have been no long-term studies of stimulant use beyond 1 year (6), and this fact is often brought up by the lay media in discussions of the treatment of ADHD (7).. To read the full article, log in using your MPFT NHS OpenAthens details.
The comparative efficacy and tolerability of methylphenidate (MPH) and neurofeedback (NF) in individuals with attention-deficit/hyperactivity disorder (ADHD) remains uncertain. This study aimed to fill this gap by means of a systematic review/meta-analysis.. To read the full article, log in using your NHS OpenAthens details.
Editorial. In this issue, results from the attention deficit hyperactivity disorder (ADHD) section of the ENIGMA (Enhanced Neuroimaging Genetics Through Meta-Analysis) consortium are reported for cortical measures (1), complementing an earlier report of intracranial volume and subcortical structures (2). Combining data from 36 sites, these reports represent the largest-sample ADHD neuroimaging studies to date (2,246 individuals with ADHD and 1,934 control subjects).. Login at top right hand side of page using your MPFT NHS OpenAthens for full text.